Matt Zuga insider trades: Acumen Pharmaceuticals (ABOS) stock buys and sales
Trades on the price chart
Daily close, with an arrow on each day they bought or sold
Companies
Where Matt reports to the SEC
Open-market buys and sales
13 trades reported on SEC Form 4, newest first
| Date | Stock | Type | Shares | Price | Value | Holding | Reported |
|---|---|---|---|---|---|---|---|
| Jan 22, 2026 | ABOS | ↓ Sell10b5-1 | 4,160 | $1.83 | $8K | Direct | Jan 23, 2026 (1d) |
| Jan 8, 2026 | ABOS | ↓ Sell10b5-1 | 6,888 | $1.82 | $13K | Direct | Jan 12, 2026 (4d) |
| Jan 7, 2026 | ABOS | ↓ Sell10b5-1 | 14,905 | $1.97 | $29K | Direct | Jan 7, 2026 (0d) |
| Feb 3, 2025 | ELUT | ↑ Buy | 420,000 | $2.50 | $1.1M | Indirect | Mar 13, 2025 (38d) |
| Jan 23, 2025 | ABOS | ↓ Sell10b5-1 | 33,266 | $1.70 | $57K | Direct | Jan 23, 2025 (0d) |
| Jan 3, 2025 | ABOS | ↓ Sell10b5-1 | 13,235 | $1.84 | $24K | Direct | Jan 7, 2025 (4d) |
| Jan 18, 2024 | ABOS | ↓ Sell10b5-1 | 4,242 | $3.71 | $16K | Direct | Jan 19, 2024 (1d) |
| Dec 5, 2022 | AZYO | ↑ Buy | 735,000 | $4.75 | $3.5M | Indirect | Dec 7, 2022 (2d) |
| Dec 8, 2021 | AZYO | ↑ Buy | 353,773 | $4.24 | $1.5M | Indirect | Dec 10, 2021 (2d) |
| Dec 8, 2021 | AZYO | ↑ Buy | 58,962 | $4.24 | $250K | Held by the Kevin L. Rakin Irrevocable T | Dec 10, 2021 (2d) |
| Oct 13, 2020 | AZYO | ↑ Buy | 441,176 | $17.00 | $7.5M | Indirect | Oct 13, 2020 (0d) |
| Nov 8, 2019 | TELA | ↑ Buy | 75,901 | $13.00 | $987K | By HighCape Partners QP, L.P. | Nov 13, 2019 (5d) |
| Nov 8, 2019 | TELA | ↑ Buy | 10,220 | $13.00 | $133K | By HighCape Partners, L.P. | Nov 13, 2019 (5d) |
Each row is one filing's trades in one stock, summed. Shares and prices are as filed, before any later stock split.
Other ABOS insiders
Open-market trades in the last 12 months
About Matt Zuga's insider trades
Matt Zuga is CFO & Chief Business Officer at Acumen Pharmaceuticals (ABOS). Since Nov 8, 2019, Matt has reported 7 open-market purchases worth $14.9M and 6 sales worth $146K on SEC Form 4. In the last 12 months: 3 sales ($50K).
6 sales (100% of the value sold) were made under a Rule 10b5-1 trading plan, which is set up months in advance and runs on a schedule, so they say little about how the insider sees the stock today.
Their filings also include grants and awards (11 filings), option exercises (3 filings), conversions (3 filings), other transactions (2 filings). These aren't open-market trades and aren't counted above.
How to read insider trades
Officers, directors and owners of more than 10% of a company must report trades in its stock on SEC Form 4, usually within two business days. Purchases with their own money are the stronger signal: insiders sell for many reasons (taxes, diversification, a house), but buy for one. See every ABOS insider trade, the latest insider trades across the market, or cluster buys, when several insiders buy the same stock within days.